Heart disease might be the leading cause of death in the United States, but, according to a recent report, it’s also one of the least searched-for diseases on the internet.

Ablacon, a Colorado-based company leveraging AI to develop an advanced mapping system to aid in the treatment of atrial fibrillation, has raised $21.5 million in a Series A funding round, the company announced.

The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.

CMS saw an influx of public commentary after it first published a draft of recommendations for revising the United States’ national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) more than a month ago. Now that the 30-day comment period is over, the agency has a decision to make.

Researchers have determined that the widespread use of genetic testing for newly diagnosed patients could lead to approximately $50 million in savings for the first year of breast cancer care in the United States.

"This study only answers the question about whether, in the first 12 months after diagnosis, costs of gene testing are likely to be offset by savings in avoided costs of chemotherapy—and the answer is yes," wrote authors of a new study published in JNCI.

The global wearable medical devices market is expected to surpass $29 billion by 2026, according to a report from Transparency Market Research (TMR), expanding at a projected compound annual growth rate (CAGR) of more than 17% over the next seven years.

The CDC’s most recent Health, United States report, released this April, reveals the extent to which racial and ethnic disparities in the U.S. affect cardiovascular care and rates of heart disease in the country.